Preview

Experimental and Clinical Gastroenterology

Advanced search

PROGNOSTIC VALUE OF THE ATROPHIA MARKERS IN GASTRIC CANCER RISK AT THE WEST SIBERIA POPULATION

Abstract

Background: atrophic gastritis (AG) associated with Helicobacter pylori (H. pylori-infection) is one of the precancerous lesions and associated with low level of serum pepsinogen I (PGI) and PGI/PGII ratio, which are also recognized like predictive markers for gastric cancer (GC) development. The aim of the study: to analyze the predictive value of biomarkers in the GC development in a prospective “case-control” study conducted in Caucasian population of Western Siberia (8 years follow-up). Material and Methods: GC cases and control were selected from population cohort of residents of Novosibirsk within the international HAPIEE project during 2003-2005 with inclusion of subjects (n=9360) of both sexes at the age of 45-69 years. Serum samples were stored at -700С. GC cases received from Population Cancer Registry until 2012 were compared with the database of HAPIEE with selection of appropriate on sex and age control in the ratio 1:2. Finally, 156 serum samples (52 - the main group and 104 - control) were available for analysis, and biomarkers were measured. The following criteria for biomarkers of atrophic gastritis were used: PGI < 30 µg/l, PGII < 3 µg/l, PGI/PGII < 3, G-17 < 1 pmol/l. Results: The mean levels of PGI and PgI/PgII ratio in the GC group was lower in comparison with the control (p < 0.005 and p< 0.0001, respectively); no difference was shown in respect to the other biomarkers. The cut-off values of atrophy have appeared above the recommended parameters: for PGI-55 µg/l (р=0.0001; OR=4.1; 95 % CI 2.0-8.4) and PGI/PGII ratio-5 (р=0.0001; OR =5.8; 95 % CI 2.7-12.4). Conditional (fixed effects) logistic regression analysis with inclusion into the model sex, age of the patients, and all biomarkers of test system showed PGI/PGII ratio as the most powerful indicator in the model (OR=2.9; 95 % CI: 1.0-8.0). Conclusions: for the first time the predictive value of low indicators of PGI and PGI/PGII ratio in GC risk development in Caucasian population for 8 years follow-up was demonstrated.

About the Authors

S. A. Kurilovich
Research Institute of Internal and Preventive Medicine - Branch of the Institute of Cytology and Genetics of SB RAS”; Novosibirsk State Medical University
Russian Federation


A. V. Belkovets
Research Institute of Internal and Preventive Medicine - Branch of the Institute of Cytology and Genetics of SB RAS”; Novosibirsk State Medical University
Russian Federation


O. V. Reshetnikov
Research Institute of Internal and Preventive Medicine - Branch of the Institute of Cytology and Genetics of SB RAS”; Novosibirsk State Medical University
Russian Federation


Yu. I. Ragino
Research Institute of Internal and Preventive Medicine - Branch of the Institute of Cytology and Genetics of SB RAS”; Novosibirsk State Medical University
Russian Federation


L. V. Scherbakova
Research Institute of Internal and Preventive Medicine - Branch of the Institute of Cytology and Genetics of SB RAS”; Novosibirsk State Medical University
Russian Federation


S. K. Malyutina
Research Institute of Internal and Preventive Medicine - Branch of the Institute of Cytology and Genetics of SB RAS”; Novosibirsk State Medical University
Russian Federation


References

1. Melton S. D., Genta M., Souza R. F. Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. // Nat. Rev. Gastroenterol. Hepatol., 2010; 7: 620-628.

2. Parkin D. M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. //CA Cancer J. Clin., 2002; 55: 74-108.

3. Давыдов М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. Москва, 2014. -226 с.

4. Davidov M. I., Axel E. M. Statistics of neoplasms in Russia and SNG, 2012. M., 2014.-226p.

5. Correa P., Piazuelo M. B., Wilson T. (2010) Pathology of gastric intestinal metaplasia: Clinical implications.// Am. J. Gastroenterol., 2010; 105: 493-498.

6. Asaka M., Kato M., Takahashi S., Fukuda Y., Sugiyama T., Ota H., Uemura N., Murakami K., Satoh K., Sugano K. Guideline for the management of Helicobacter pylori in Japan: 2009 revised edition. // J. Helicobacter, 2010; 15: 1-20.

7. Miki K., Ichinose M., Shimizu A., Huang S. C., Oka H., Furihata C., Matsushima T., Takahashi K. (1987) Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol. Jpn. 1987; 22: 133-141.

8. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - “ABC method”. Proc Jpn Acad Ser B Phys Biol Sci., 2011; 87(7): 405-414.

9. Vaananen H, Vauhkonen M, Helske T, et al. Nonendoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study.// Eur J Gastroenterol Hepatol., 2003; 15: 885-891

10. Syrjanen K. J., Sipponen P., Harkonen M., Peetsalu A. and Korpela S. Accuracy of GastroPanel testing in detection of atrophic gastritis. // Eur J Gastroenterol Hepatol., 2015; 27: 102-104

11. Oishi Y., Kiyohara Y., Kubo M., Tanaka K., Tanizaki Y., Ninomiya T., Doi Y., Shikata K., Yonemoto K., Shirota T., Matsumoto T. and Iida M. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study.// Am J Epidemiol/, 2006; 163: 629-637

12. Pasechnikov V., Chukov S., Fedorov E., Kikuste I. and Leja M. Gastric cancer: prevention, screening and early diagnosis. //World J Gastroenterol., 2014; 20: 13842-13862

13. Oishi Y., Kiyohara Y., Kubo M., Tanaka K., Tanizaki Y. et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. //Am J Epidemiol/, 2006; 163: 629-637

14. Yanaoka K., Oka M., Yoshimura N., Mukoubayashi C., Enomoto S., Iguchi M. et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. //Int J Cancer, 2008; 123: 917-926

15. Peasey A., Bobak M., Kubinova R., Malyutina S., Pajak A. et al. Determinants of cardiovascular disease and other noncommunicable diseases in Central and Eastern Europe: rationale and design of the HAPIEE study. //BMC Pub Health, 2006; 6: 255

16. Yanaoka K., Oka M., Yoshimura N., Mukoubayashi C., Enomoto S. et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacterpylori antibody levels. //Int J Cancer, 2008; 123: 917-926.

17. Mizuno S., Miki I., Ishida T., Yoshida M., Onoyama M. et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci/, 2010; 55: 3132-3137

18. Shiota S., Murakawi K., Suzuki R., Fujioka T. and Yamaoka Y. Helicobacter pylori infection in Japan. Exp Rev Gastroenterol Hepatol 7: 35-40, 2013.

19. Ueda J., Gosho M., Inui Y., Matsuda T., Sakakibara M. et al. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. //Helicobacter, 2014; 19: 105-110

20. Lim S. H., Kwon J. W., Kim N., Kim G. H., Kang J. M. et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. // BMC Gastroenterol/, 2013; 13: 104

21. Mizuno S., Miki I., Ishida T., Yoshida M., Onoyama M., Azuma T., Habu Y., Inokuchi H., Ozasa K., Miki K., Watanabe Y. (2010) Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis.// Dig. Dis. Sci., 2010; 55: 3132-37.

22. Kodashima S., Miki K., Fujishiro M., Yahagi N., Koike K. (2010) Usefulness of a new gastric cancer screening program using the combination assay of serum anti-Helicobacter pylori IgG antibody and the serum pepsinogen levels. //Am. J. Gastroenterol., 2010; 105: S 38.

23. Weck M. N., Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. // Cancer Epidemiol Biomarkers Prev, 2006; 15(6):1083-94.

24. Agreus L., Kuipers E. J., Kupcinskas L., Malfertheiner P., Di Mario.F, Leja M. et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. // Scand J Gastroenterol., 2012; 47: 136-147

25. Storskrubb T., Aro P., Ronkainen J., Sipponen P., Nyhlin H. et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. // Scand J Gastroenterol, 2008; 43: 1448-55.

26. Syrjanen K. J., Sipponen P., Harkonen M., Peetsalu A. and Korpela S. Accuracy of GastroPanel testing in detection of atrophic gastritis.// Eur J Gastroenterol Hepatol., 2015; 27: 102-104

27. Leja M., Kupcinskas L., Funka K., Sudraba A., Jonaitis L. et al. Value of gastrin-17 in detecting antral atrophy. // Adv Med Sci., 2011; 56:145-150

28. Белковец А. В., Курилович С. А., Решетников О. В., Рагино Ю. И., Щербакова Л. В. Распространенность и особенности фундального атрофического гастрита в популяции с высоким уровнем Helicobacter pylori инфекции. //Эксп. Клин. Гастроэнтерология, 2016; 133(9): 8-13.

29. Belkovets A. V., Kurilovich S. A., Reshetnikov O. V., Ragino Yu.I., Shcerbakova L. V. Prevalence and peculiarity of corpus gastritis in population with high level of Helicobacter pylori-infection.// Exp. Clin. Gastroenterol., 2016; 133(9):8-13


Review

For citations:


Kurilovich S.A., Belkovets A.V., Reshetnikov O.V., Ragino Yu.I., Scherbakova L.V., Malyutina S.K. PROGNOSTIC VALUE OF THE ATROPHIA MARKERS IN GASTRIC CANCER RISK AT THE WEST SIBERIA POPULATION. Experimental and Clinical Gastroenterology. 2017;(11):13-21. (In Russ.)

Views: 221


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)